<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychopharmacology (Berl)</journal-id><journal-id journal-id-type="iso-abbrev">Psychopharmacology (Berl.)</journal-id><journal-title-group><journal-title>Psychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">0033-3158</issn><issn pub-type="epub">1432-2072</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25533997</article-id><article-id pub-id-type="pmc">4432080</article-id><article-id pub-id-type="publisher-id">3837</article-id><article-id pub-id-type="doi">10.1007/s00213-014-3837-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Inverse fluoxetine effects on inhibitory brain activation in non-comorbid boys with ADHD and with ASD</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chantiluke</surname><given-names>Kaylita</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Barrett</surname><given-names>Nadia</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Giampietro</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Santosh</surname><given-names>Paramala</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Brammer</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Simmons</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Murphy</surname><given-names>Declan G.</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rubia</surname><given-names>Katya</given-names></name><address><phone>0044-207-8480463</phone><email>katya.rubia@kcl.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Department of Child and Adolescent Psychiatry/MRC Center for Social, Genetic and Developmental Psychiatry (SGDP), Institute of Psychiatry, King&#x02019;s College London, 16 De Crespigny Park, PO46, London, SE5 8AF UK </aff><aff id="Aff2"><label/>South London and Maudsley NHS Trust, London, UK </aff><aff id="Aff3"><label/>Department of Neuroimaging, Institute of Psychiatry, King&#x02019;s College London, London, UK </aff><aff id="Aff4"><label/>NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Trust and Institute of Psychiatry, King&#x02019;s College London, London, UK </aff><aff id="Aff5"><label/>Department of Forensic and Developmental Sciences &#x00026; the Sackler Institute for Translational Neurodevelopment, Institute of Psychiatry, King&#x02019;s College London, London, UK </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>232</volume><issue>12</issue><fpage>2071</fpage><lpage>2082</lpage><history><date date-type="received"><day>1</day><month>11</month><year>2013</year></date><date date-type="accepted"><day>3</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2014</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Rationale</title><p>Attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) are often comorbid and have both performance and brain dysfunctions during motor response inhibition. Serotonin agonists modulate motor response inhibition and have shown positive behavioural effects in both disorders.</p></sec><sec><title>Aims</title><p>We therefore used functional magnetic resonance imaging (fMRI) to investigate the so far unknown shared and disorder-specific inhibitory brain dysfunctions in these two disorders, as well as the effects of a single dose of the selective serotonin reuptake inhibitor fluoxetine.</p></sec><sec><title>Methods</title><p>Age-matched boys with ADHD (18), ASD (19) and healthy controls (25) were compared with fMRI during a stop task measuring motor inhibition. Patients were scanned twice, under either an acute dose of fluoxetine or placebo in a double-blind, placebo-controlled randomised design. Repeated measures analyses within patients assessed drug effects. To test for potential normalisation effects of brain dysfunctions, patients under each drug condition were compared to controls.</p></sec><sec><title>Results</title><p>Under placebo, relative to controls, ASD boys showed overactivation in left and right inferior frontal cortex (IFC), while ADHD boys showed disorder-specific underactivation in orbitofrontal cortex (OFC) and basal ganglia. Under fluoxetine, the prefrontal dysfunctions were no longer observed, due to inverse effects of fluoxetine on these activations: fluoxetine downregulated IFC and OFC activation in ASD but upregulated them in ADHD.</p></sec><sec><title>Conclusions</title><p>The findings show that fluoxetine normalises frontal lobe dysfunctions in both disorders via inverse effects, downregulating abnormally increased frontal activation in ASD and upregulating abnormally decreased frontal activation in ADHD, potentially reflecting inverse baseline serotonin levels in both disorders.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00213-014-3837-2) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>ADHD</kwd><kwd>ASD</kwd><kwd>Motor response inhibition</kwd><kwd>Stop task</kwd><kwd>fMRI</kwd><kwd>Serotonin</kwd><kwd>Fluoxetine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder defined by age-inappropriate levels of inattention, impulsivity and hyperactivity (American Psychiatric Association <xref ref-type="bibr" rid="CR2">2000</xref>). Autism spectrum disorder (ASD) is defined by impairments in communication, social interaction and by restricted and repetitive behaviours (American Psychiatric Association <xref ref-type="bibr" rid="CR2">2000</xref>). There is increasing evidence for comorbidity between disorders (Rommelse et al. <xref ref-type="bibr" rid="CR57">2011</xref>; Simonoff et al. <xref ref-type="bibr" rid="CR70">2008</xref>; van der Meer et al. <xref ref-type="bibr" rid="CR75">2012</xref>) and shared executive function deficits (Corbett et al. <xref ref-type="bibr" rid="CR14">2009</xref>; Geurts et al. <xref ref-type="bibr" rid="CR24">2004</xref>), in particular in motor response inhibition (Alderson et al. <xref ref-type="bibr" rid="CR1">2007</xref>; Corbett et al. <xref ref-type="bibr" rid="CR14">2009</xref>; Lipsyzc and Schachar <xref ref-type="bibr" rid="CR37">2010</xref>; Robinson et al. <xref ref-type="bibr" rid="CR55">2009</xref>), albeit less consistently in ASD (Ozonoff and Strayer <xref ref-type="bibr" rid="CR48">1997</xref>; Raymaekers et al. <xref ref-type="bibr" rid="CR53">2007</xref>). Furthermore, this has been associated with impulsiveness in ADHD and motor stereotypies in ASD (Langen et al. <xref ref-type="bibr" rid="CR36">2011</xref>). This overlap was highlighted by recent changes to the DSM-V that allows co-diagnosis of ADHD and ASD (<ext-link ext-link-type="uri" xlink:href="http://www.dsm5.org/">http://www.dsm5.org/</ext-link>).</p><p>In ADHD, there is consistent evidence of underactivation compared to controls in inferior/orbitofrontal frontal cortex (IFC/OFC), supplementary motor area (SMA) and caudate/thalamus during inhibition tasks (Cubillo et al. <xref ref-type="bibr" rid="CR16">2012</xref>; Rubia <xref ref-type="bibr" rid="CR58">2011</xref>; Rubia et al. <xref ref-type="bibr" rid="CR59">2014</xref>; Rubia et al. <xref ref-type="bibr" rid="CR62">1999</xref>; Rubia et al. <xref ref-type="bibr" rid="CR65">2005b</xref>; Cortese et al. <xref ref-type="bibr" rid="CR15">2012</xref>; Hart et al. <xref ref-type="bibr" rid="CR29">2013</xref>). In children with ASD, however, no study has investigated the neurofunctional underpinnings of response inhibition. In adults with ASD, fMRI studies report inconsistent findings of increased activation in left IFC and decreased activation in right IFC and anterior cingulate cortex (ACC) during the go/no-go task (Kana et al. <xref ref-type="bibr" rid="CR32">2007</xref>; Schmitz et al. <xref ref-type="bibr" rid="CR68">2006</xref>). Therefore, a key question is whether the underlying neurobiology of shared cognitive phenotypes is shared or disorder-specific.</p><p>Serotonin (SE) is involved in impulsiveness and motor inhibition (Robbins et al. <xref ref-type="bibr" rid="CR54">2010</xref>) and although selective serotonin reuptake inhibitors (SSRIs) such as citalopram had no effect on SSRT in healthy subjects (Chamberlain et al. <xref ref-type="bibr" rid="CR10">2006</xref>), fMRI studies showed that SSRIs and acute tryptophan depletion (ATD), which enhance/reduce SE levels, enhance/decrease inhibitory IFC/OFC-striatal activation, respectively (Lamar et al. <xref ref-type="bibr" rid="CR34">2012</xref>; Lamar et al. <xref ref-type="bibr" rid="CR35">2009</xref>; Rubia et al. <xref ref-type="bibr" rid="CR61">2005a</xref>).</p><p>Furthermore, there is evidence that 5-HT is involved in the pathology of both ADHD and ASD. Thus, polymorphisms of serotonergic genes have been associated with both ADHD and ASD (Rommelse et al. <xref ref-type="bibr" rid="CR56">2010</xref>; Sinzig and Lehmkuhl <xref ref-type="bibr" rid="CR71">2007</xref>). Moreover, biochemical serotonergic abnormalities have been implicated in both ADHD (Oades <xref ref-type="bibr" rid="CR46">2007</xref>) and ASD (Zafeiriou et al. <xref ref-type="bibr" rid="CR79">2009</xref>). Despite evidence for SE abnormalities in both disorders, few studies have investigated the clinical efficacy of SSRIs in ADHD and ASD. The SSRI fluoxetine, for example, has been shown to improve inattentiveness and hyperactivity in comorbid children with ADHD (Barrickman et al. <xref ref-type="bibr" rid="CR4">1991</xref>; Gammon and Brown <xref ref-type="bibr" rid="CR23">1993</xref>; Quintana et al. <xref ref-type="bibr" rid="CR52">2007</xref>) and to improve communication, social interaction and stereotyped behaviours in children with ASD (DeLong et al. <xref ref-type="bibr" rid="CR19">2002</xref>; DeLong et al. <xref ref-type="bibr" rid="CR20">1998</xref>; Hollander et al. <xref ref-type="bibr" rid="CR30">2005</xref>), albeit citalopram was not effective (King et al. <xref ref-type="bibr" rid="CR33">2009</xref>).</p><p>Given the evidence for abnormalities in SE (Oades <xref ref-type="bibr" rid="CR46">2007</xref>; Zafeiriou et al. <xref ref-type="bibr" rid="CR79">2009</xref>) and inhibition in both disorders (Alderson et al. <xref ref-type="bibr" rid="CR1">2007</xref>; Corbett et al. <xref ref-type="bibr" rid="CR14">2009</xref>; Geurts et al. <xref ref-type="bibr" rid="CR24">2004</xref>; Robinson et al. <xref ref-type="bibr" rid="CR55">2009</xref>; Rommelse et al. <xref ref-type="bibr" rid="CR57">2011</xref>) and serotonergic mediation of inhibitory control (Anderson et al. <xref ref-type="bibr" rid="CR3">2008</xref>; Lamar et al. <xref ref-type="bibr" rid="CR34">2012</xref>; Lamar et al. <xref ref-type="bibr" rid="CR35">2009</xref>; Robbins et al. <xref ref-type="bibr" rid="CR54">2010</xref>; Rubia et al. <xref ref-type="bibr" rid="CR61">2005a</xref>), an important question that may elucidate the&#x000a0;potential neurotransmitter underpinnings of these&#x000a0;cognitive abnormalities is whether SE modulates the inhibitory network in <italic>both</italic> ADHD and ASD and whether this modulation differs between disorders.</p><p>The aim of this fMRI study was therefore to investigate (1) shared and disorder-specific brain dysfunctions in ADHD and ASD boys during a tracking stop task and (2) shared and disorder-specific neurofunctional effects of an acute dose of fluoxetine on these inhibitory (dys)functions in both disorders. It has been argued that inferior frontal activation during stop task performance may be confounded by the attentional oddball effect of the low frequency appearance of stop signals (Hampshire et al. <xref ref-type="bibr" rid="CR27">2010</xref>; Pauls et al. <xref ref-type="bibr" rid="CR49">2012a</xref>). Given that in this study we were particularly interested in the effects of fluoxetine on inhibitory rather than on attention networks, in our fMRI analysis&#x000a0;we contrasted successful stop trials with failed stop trials in order to control for the attentional oddball effect of the low frequency appearance of the stop trials.</p><p>We hypothesised that, under placebo, ADHD boys compared to controls would show decreased IFC and caudate activation (Cortese et al. <xref ref-type="bibr" rid="CR15">2012</xref>; Cubillo et al. <xref ref-type="bibr" rid="CR16">2012</xref>; Cubillo et al. <xref ref-type="bibr" rid="CR17">2014</xref>; Hart et al. <xref ref-type="bibr" rid="CR29">2013</xref>; Rubia <xref ref-type="bibr" rid="CR58">2011</xref>; Rubia et al. <xref ref-type="bibr" rid="CR62">1999</xref>; Rubia et al. <xref ref-type="bibr" rid="CR65">2005b</xref>), whereas ASD boys would show increased left frontal activation (Schmitz et al. <xref ref-type="bibr" rid="CR68">2006</xref>). We further hypothesised that fluoxetine compared to placebo, given its beneficial effects on symptoms, would normalise the abnormal activations in each disorder, i.e. it would increase the reduced fronto-striatal activation in ADHD, but reduce the increased left frontal abnormalities in ASD.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Participants</title><p>Sixty-two right-handed boys (Edinburgh Handedness Inventory) (Oldfield <xref ref-type="bibr" rid="CR47">1971</xref>) (25 controls, 18 with ADHD and 19 with ASD) aged 10&#x02013;17, IQ&#x02009;&#x0003e;&#x02009;70 (Wechsler Abbreviated Scale of Intelligence-Revised (WASI-R) (Wechsler <xref ref-type="bibr" rid="CR76">1999</xref>) participated in this study.</p><p>ADHD boys had a clinical diagnosis of non-comorbid ADHD, inattentive/hyperactive-impulsive combined subtype, as assessed by an experienced child psychiatrist using the standardised Maudsley diagnostic interview that assesses ADHD according to DSM-IV criteria (Goldberg and Murray <xref ref-type="bibr" rid="CR25">2006</xref>). They scored above clinical threshold for ADHD symptoms on the Strengths and Difficulties Questionnaire (SDQ) (Goodman and Scott <xref ref-type="bibr" rid="CR26">1999</xref>) and the Conners&#x02019; Parent Rating Scale-Revised (CPRS-R) (Conners et al. <xref ref-type="bibr" rid="CR13">1998</xref>). Four of the ADHD boys were medication-na&#x000ef;ve, three had ceased taking methylphenidate for a year (1), or 3&#x000a0;months (2) and 11 received chronic stimulants, but had a 48-h medication washout prior to scanning. ADHD boys were excluded if they scored above 15 on the Social Communication Questionnaire (SCQ) (Rutter et al. <xref ref-type="bibr" rid="CR67">2003</xref>).</p><p>ASD diagnosis was made using ICD-10 (World Health Organisation (WHO) <xref ref-type="bibr" rid="CR78">1994</xref>) diagnostic criteria and confirmed by the Autism Diagnostic Interview-Revised (ADI&#x02013;R) (Lord et al. <xref ref-type="bibr" rid="CR40">1994</xref>) and the Autism Diagnostic Observation Schedule (ADOS) (Lord et al. <xref ref-type="bibr" rid="CR39">2000</xref>). All ASD subjects were medication-na&#x000ef;ve apart from one patient, who took melatonin (but underwent a 2-week medication washout). ASD exclusion criteria included a score above 7 on the hyperactivity/inattention subscale of the SDQ or a <italic>t</italic> score above 70 on the DSM-IV subscale of the CPRS-R.</p><p>Exclusion criteria for all were comorbidity with other psychiatric or neurological disorders and drug/alcohol dependency. Patients were recruited from local clinics and support groups.</p><p>Patients were scanned twice in a double-blind, randomised, placebo-controlled design, using a Latin square randomization design for counter-balanced effects. Due to the half-life of fluoxetine (1&#x02013;3&#x000a0;days) and its metabolite norfluoxetine (5&#x02013;16&#x000a0;days) (Wong et al. <xref ref-type="bibr" rid="CR77">1995</xref>), each scan was 3&#x02013;4&#x000a0;weeks apart. To ensure that fluoxetine had reached its peak plasma levels, after 5&#x02013;8&#x000a0;h (Wong et al. <xref ref-type="bibr" rid="CR77">1995</xref>), patients were scanned 5&#x000a0;h after administration. Liquid fluoxetine was titrated to age and weight (see supplement). Placebo was equivalent amounts of peppermint water with similar taste to fluoxetine.</p><p>Twenty-five healthy, handedness and age-matched boys were recruited by advertisement and scored below clinical thresholds on the SDQ, SCQ and CPRS.</p><p>Participants gave written informed consent/assent. The study was approved by the local Ethics Committee. Participants were paid &#x000a3;50 for each scan.</p><p>For recruitment, demographic and clinical details of participants, see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Sample characteristics for healthy control boys and patients with ADHD and ASD</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>Controls (25) mean (SD)</th><th>ADHD (18) mean (SD)</th><th>ASD (19) mean (SD)</th></tr></thead><tbody><tr><td>Age (years)</td><td>13.4 (2.4)</td><td>14.3 (1.8)</td><td>14.7 (2.0)</td></tr><tr><td>IQ</td><td>109 (13)</td><td>95 (11)</td><td>112 (15)</td></tr><tr><td>SDQ hyperactive-impulsive/inattentive subscale</td><td>1.8 (1.6)</td><td>9.2 (0.9)</td><td>4.5 (1.8)</td></tr><tr><td>SDQ&#x02014;emotional distress subscale</td><td>0.5 (0.8)</td><td>3.6 (3.0)</td><td>4.2 (3.0)</td></tr><tr><td>SDQ&#x02014;conduct subscale</td><td>0.3 (0.7)</td><td>5.0 (2.4)</td><td>2.1 (2.0)</td></tr><tr><td>SDQ&#x02014;peer relations subscale</td><td>.6 (1.1)</td><td>3.4 (2.5)</td><td>6.1 (2.4)</td></tr><tr><td>SDQ&#x02014;prosocial behaviour subscale</td><td>9.1 (1.3)</td><td>6.7 (2.3)</td><td>5.1 (2.3)</td></tr><tr><td>SDQ&#x02014;total scores</td><td>3.3 (2.9)</td><td>21.2 (4.9)</td><td>16.8 (5.7)</td></tr><tr><td>SCQ total</td><td>1.6 (2.7)</td><td>7.0 (3.4)</td><td>23.5 (5.5)</td></tr><tr><td>CPRS-R total <italic>T</italic> score</td><td>44 (3)</td><td>83 (7)</td><td>57 (8)</td></tr><tr><td>ADOS communication scores</td><td>&#x02013;</td><td>&#x02013;</td><td>2 (1)</td></tr><tr><td>ADOS social interaction scores</td><td>&#x02013;</td><td>&#x02013;</td><td>7 (4)</td></tr><tr><td>ADOS communication and social scores</td><td>&#x02013;</td><td>&#x02013;</td><td>9 (5)</td></tr><tr><td>ADOS stereotyped behaviour scores</td><td>&#x02013;</td><td>&#x02013;</td><td>1 (1)</td></tr><tr><td>ADI communication scores</td><td>&#x02013;</td><td>&#x02013;</td><td>14 (4)</td></tr><tr><td>ADI social Interaction scores</td><td>&#x02013;</td><td>&#x02013;</td><td>17 (5)</td></tr><tr><td>ADI stereotyped scores</td><td>&#x02013;</td><td>&#x02013;</td><td>6 (3)</td></tr></tbody></table><table-wrap-foot><p>
<italic>SDQ</italic> Strengths and Difficulties Questionnaire, <italic>SCQ</italic> Social Communication Questionnaire, <italic>CPRS-R</italic> Conners&#x02019; Parent Rating Scale-Revised, <italic>ADOS</italic> Autism Diagnostic Observation Schedule, <italic>ADI</italic> Autism Diagnostic Interview</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>FMRI paradigm: stop task</title><p>Subjects practised the task once prior to each scan under supervision of the researcher who made sure the participants understood the task and performed accordingly (by inhibiting more or less 50&#x000a0;% of trials). The 8&#x000a0;min 49&#x000a0;s&#x000a0;minute visual tracking stop task requires withholding of an already triggered motor response to a go stimulus when it is followed unpredictably by a stop signal (Cubillo et al. <xref ref-type="bibr" rid="CR17">2014</xref>; Rubia et al. <xref ref-type="bibr" rid="CR60">2011</xref>; Rubia et al. <xref ref-type="bibr" rid="CR64">2003</xref>; Rubia et al. <xref ref-type="bibr" rid="CR65">2005b</xref>; Rubia et al. <xref ref-type="bibr" rid="CR66">2007</xref>). Subjects have to respond as quickly as possible to left or right pointing &#x0201c;go&#x0201d; arrows (500&#x000a0;ms duration, 80&#x000a0;% of 294 trials) with a left or right (thumb) button press, followed by a gap of 1100 to 1500&#x000a0;ms (which makes up a mean trial length of 1.8&#x000a0;s; jittered between 1.6 and 2&#x000a0;s to optimise statistical efficiency). In 20&#x000a0;% of trials (60), pseudo-randomly interspersed, and at least 3 repetition times apart for adequate separation of the hemodynamic response, go signals are followed (about 250&#x000a0;ms later) by arrows pointing upwards (300&#x000a0;ms duration) (stop signals), and subjects have to inhibit their motor response. A tracking algorithm changes the time interval between go and stop-signal onsets according to each subject&#x02019;s inhibitory performance, which is recalculated after each stop signal based on the average percentage of inhibition over previous stop trials to provide 50&#x000a0;% successful and 50&#x000a0;% unsuccessful inhibition trials (Supplementary Figure&#x000a0;<xref rid="MOESM1" ref-type="media">S1</xref>).</p><p>Given that the contrast of stop-go trials is confounded by the attentional oddball effect of the low frequency of stop trials (20&#x000a0;%) relative to go trials (80&#x000a0;%), which also activates IFC (Hampshire et al. <xref ref-type="bibr" rid="CR27">2010</xref>; Pauls et al. <xref ref-type="bibr" rid="CR50">2012b</xref>), for the fMRI analysis, brain activation to the 50&#x000a0;% unsuccessful stop trials was subtracted from the 50&#x000a0;% successful stop trials, controlling for the attentional oddball effect of the infrequent stop signal appearance.</p><p>The dependent inhibition variable is the stop signal reaction time (SSRT), calculated by subtracting the mean stop signal delay (SSD: the average time between go and stop signal at which the subject managed to inhibit to 50&#x000a0;% of trials) from the mean reaction time (MRT) to go trials, i.e. MRT-SSD (Logan et al. <xref ref-type="bibr" rid="CR38">1997</xref>). MRT, intrasubject standard deviation of MRT, and omission error percentage are variables of the executive process of the task.</p></sec></sec><sec id="Sec5"><title>Data analysis</title><sec id="Sec6"><title>Analysis of performance data</title><p>MANOVAs compared performance variables between controls and the two patient groups under placebo and between controls and the two patient groups under fluoxetine. Multiple repeated-measures ANOVAs within the two patient groups with group (ADHD, ASD) as independent factor and drug condition (placebo/fluoxetine) as repeated measures were conducted to test for group by medication interaction effects on performance.</p></sec><sec id="Sec7"><title>FMRI image acquisition</title><p>Gradient-echo echoplanar MR imaging (EPI) data were acquired on a General Electric Signa 3T Horizon HDx system at the Centre for Neuroimaging Sciences, Institute of Psychiatry, King&#x02019;s College London, UK. A semiautomated quality control procedure ensured consistent image quality. A quadrature birdcage headcoil was used for RF transmission and reception. In each of 28 non-contiguous planes parallel to the anterior-posterior commissure, 296&#x000a0;T2*-weighted MR images depicting BOLD contrast covering the whole brain were acquired with TE&#x02009;=&#x02009;30&#x000a0;ms, TR&#x02009;=&#x02009;1.8&#x000a0;s, flip angle&#x02009;=&#x02009;75&#x000b0;, in-plane voxel-size&#x02009;=&#x02009;3&#x000a0;mm, slice thickness&#x02009;=&#x02009;5.5&#x000a0;mm and slice-skip&#x02009;=&#x02009;0.5&#x000a0;mm. A whole-brain high-resolution structural scan (inversion recovery gradient echo planar image) on which to superimpose the individual activation maps, was also acquired in the inter-commissural plane with TE&#x02009;=&#x02009;30&#x000a0;ms, TR&#x02009;=&#x02009;3&#x000a0;s, flip angle&#x02009;=&#x02009;90&#x000b0;, 43 slices, slice thickness&#x02009;=&#x02009;3.0&#x000a0;mm, slice skip&#x02009;=&#x02009;0.3&#x000a0;mm and in-plane voxel-size&#x02009;=&#x02009;1.875&#x000a0;mm.</p><p>All subjects performed three other fMRI tasks which are not reported here.</p></sec><sec id="Sec8"><title>FMRI image analysis</title><p>The XBAM software package was used (<ext-link ext-link-type="uri" xlink:href="http://www.brainmap.co.uk/">http://www.brainmap.co.uk/</ext-link>) (Brammer et al. <xref ref-type="bibr" rid="CR5">1997</xref>) which makes no normality assumptions (often violated in fMRI data), but instead uses median statistics to control outlier effects and permutation rather than normal theory-based inference (Thirion et al. <xref ref-type="bibr" rid="CR74">2007</xref>).</p><p>Individual- and group-level analyses are described in further detail elsewhere (Brammer et al. <xref ref-type="bibr" rid="CR5">1997</xref>; Cubillo et al. <xref ref-type="bibr" rid="CR17">2014</xref>; Rubia et al. <xref ref-type="bibr" rid="CR64">2003</xref>; Rubia et al. <xref ref-type="bibr" rid="CR65">2005b</xref>; Rubia et al. <xref ref-type="bibr" rid="CR66">2007</xref>) and in the supplementary material. Briefly, the fMRI data were realigned to minimise motion-related artefacts and smoothed using a Gaussian filter (FWHM 8.82&#x000a0;mm) (Bullmore et al. <xref ref-type="bibr" rid="CR7">1999a</xref>). Further data analysis included slice timing correction and the residual effects of motion were regressed out from the time series (using the estimated motion parameters) before fitting a general linear model. Time-series analysis of individual subject activation was performed with a wavelet-based resampling method previously described (Bullmore et al. <xref ref-type="bibr" rid="CR8">2001</xref>). We convolved the task epoch of the contrasts of interest (i.e. successful stop&#x02014;implicit go trials; failed stop trials&#x02014;implicit go trials) and the higher level contrast (successful stop-go trials minus unsuccessful stop-go trials) with two Poisson model functions (delays of 4 and 8&#x000a0;s). Individual activation maps were recalculated by testing the goodness-of-fit of this convolution with the BOLD time series; the goodness-of-fit calculation used the ratio of the sum of squares of deviations from the mean intensity value due to the model (fitted time series) divided by the sum of squares due to the residuals (original time series minus model time series). This statistic, the sum of squares (SSQ) ratio, was used in further analyses. Using rigid body and affine transformation, the individual maps were registered into Talairach standard space. A group brain activation map was then produced for each medication condition and each experimental condition (see supplementary material).</p></sec><sec id="Sec9"><title>ANCOVA between-group difference analyses</title><p>For between-group comparisons between controls and patients under either placebo or fluoxetine, one-way ANCOVA analyses with group as factor and rotational and translation movement in Euclidian 3-D space as covariate, were conducted using randomization-based tests for voxel or cluster-wise differences as described in detail elsewhere (Bullmore et al. <xref ref-type="bibr" rid="CR8">2001</xref>; Bullmore et al. <xref ref-type="bibr" rid="CR9">1999b</xref>). For these between-group comparisons, less than one false activated cluster was expected at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 for voxel and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 for cluster comparisons. Given that right IFC was an a priori hypothesised region, we used a more lenient cluster level threshold of <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 and also conducted a region of interest analysis using the IFC as a mask. Then the standardised BOLD response values for each participant were extracted for the significant clusters of the ANCOVA analyses and post hoc <italic>t</italic>-tests (correcting for multiple comparisons using least significant difference (LSD)) were conducted to identify the direction of the group differences.</p></sec><sec id="Sec10"><title>ANCOVA within-patient interaction effects</title><p>A 2&#x02009;&#x000d7;&#x02009;2 ANCOVA (2 medication conditions, 2 groups) with rotational and translation movement as covariate was conducted using randomised-based testing for voxel or cluster-wise differences as described elsewhere (Bullmore et al. <xref ref-type="bibr" rid="CR8">2001</xref>). Less than one false positive activation cluster was expected at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 at voxel and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 at cluster level. For our a priori hypothesised region in right IFC, a more lenient <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 was used as well as a region of interest analysis using the IFC as a mask. Statistical measures of BOLD response for each participant were then extracted in each of the significant clusters and post hoc <italic>t</italic> tests (corrected for multiple comparisons with LSD) were conducted to identify the direction of the interaction effects.</p></sec></sec><sec id="Sec11" sec-type="results"><title>Results</title><sec id="Sec12"><title>Participant characteristics</title><p>ANOVAs showed no significant group differences in age (<italic>F</italic> (df&#x02009;=&#x02009;2,61)&#x02009;=&#x02009;3; n.s.) but in IQ (<italic>F</italic> (df&#x02009;=&#x02009;2,61)&#x02009;=&#x02009;10, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) which was significantly lower in ADHD relative to control and ASD boys (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.005), who did not differ. Given that ADHD children have typically lower IQ than their healthy peers (Bridgett and Walker <xref ref-type="bibr" rid="CR6">2006</xref>), data were not covaried for IQ, as covarying for a measure that is associated with the condition would violate ANCOVA assumptions (Dennis et al. <xref ref-type="bibr" rid="CR21">2009</xref>). Nonetheless, to assess the potential impact of IQ, analyses were repeated with IQ as covariate. For group differences in clinical measures, see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p></sec><sec id="Sec13"><title>Performance data</title><p>As expected, all subjects achieved approximately 50&#x000a0;% probability of inhibition, suggesting the algorithm was successful and there were no differences between controls and patient groups in this measure for either placebo (<italic>F</italic> (df&#x02009;=&#x02009;2,61)&#x02009;=&#x02009;1.2; <italic>p</italic>&#x02009;=&#x02009;n.s.) nor fluoxetine (<italic>F</italic> (df&#x02009;=&#x02009;2,61)&#x02009;=&#x02009;2.7, <italic>p</italic>&#x02009;=&#x02009;n.s.) nor were there any group or group by medication interaction effects for the within-patients analysis (F (df&#x02009;=&#x02009;2,61)&#x02009;&#x0003c;&#x02009;1, <italic>p</italic>&#x02009;=&#x02009;n.s.). MANOVA showed a trend for a significant group effect for placebo (<italic>F</italic> (df&#x02009;=&#x02009;8,114); <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.08), which was due to increased omission errors between controls and patients under placebo (<italic>F</italic> (df&#x02009;=&#x02009;2,61)&#x02009;=&#x02009;4, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.02). Post hoc analyses (corrected for multiple testing using least significance difference (LDS)) showed that this was due to ADHD boys having increased omission errors than both control (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) and ASD boys (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). MANOVA for fluoxetine showed no significant group effect (<italic>F</italic> (df&#x02009;=&#x02009;2,61)&#x02009;=&#x02009;1.2, <italic>p</italic>&#x02009;=&#x02009;n.s.).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Performance measures for the stop task for healthy controls, ADHD and ASD groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Performance measure</th><th colspan="2">Controls</th><th colspan="2">ADHD placebo</th><th colspan="2">ADHD fluoxetine</th><th colspan="2">ASD placebo</th><th colspan="2">ASD fluoxetine</th></tr><tr><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th></tr></thead><tbody><tr><td>SSRT</td><td>161</td><td>107</td><td>132</td><td>81</td><td>142</td><td>109</td><td>140</td><td>125</td><td>142</td><td>103</td></tr><tr><td>PI</td><td>51</td><td>3</td><td>50</td><td>3</td><td>49</td><td>4</td><td>50</td><td>3</td><td>49</td><td>4</td></tr><tr><td>SSD</td><td>462</td><td>23</td><td>497</td><td>27</td><td>490</td><td>30</td><td>479</td><td>27</td><td>480</td><td>29</td></tr><tr><td>MRT to go trials</td><td>623</td><td>104</td><td>629</td><td>86</td><td>632</td><td>109</td><td>618</td><td>102</td><td>622</td><td>113</td></tr><tr><td>SD for MRT to go trials</td><td>174</td><td>39</td><td>194</td><td>44</td><td>194</td><td>60</td><td>168</td><td>39</td><td>166</td><td>43</td></tr><tr><td>Omission errors<sup>a</sup>
</td><td>5</td><td>5</td><td>9</td><td>8</td><td>9</td><td>9</td><td>3</td><td>5</td><td>3</td><td>3</td></tr></tbody></table><table-wrap-foot><p>
<italic>PI</italic> percentage inhibition, <italic>SSRT</italic> stop signal reaction time, <italic>SSD</italic> average stop signal delay, <italic>MRT</italic> mean reaction time</p><p>SD = intrasubject variability of reaction time (in ms)</p><p>
<sup>a</sup>ADHD &#x0003e; C, ASD</p></table-wrap-foot></table-wrap></p><p>Within the patient groups there were no significant group (df&#x02009;=&#x02009;1,35) or group by medication interaction effects (df&#x02009;=&#x02009;1,35) for any variables (<italic>F</italic>&#x02009;&#x0003c;&#x02009;1 for all measures).</p><p>Given that ADHD patients performed the task twice, but controls only once, we also measured practice effects in the ADHD group using repeated measures <italic>t</italic> tests between performance measures at scans 1 and 2. No significant differences were found (<italic>F</italic> (df&#x02009;=&#x02009;1,17)&#x02009;=&#x02009;0.02, <italic>p</italic>&#x02009;=&#x02009;n.s.).</p></sec><sec id="Sec14"><title>FMRI data</title><sec id="Sec15"><title>Movement</title><p>The Euclidean formula described below was used to produce a 3-D movement value known as <italic>d</italic> which is representative of movement in <italic>x</italic>, <italic>y</italic> and <italic>z</italic>. The formula was used to produce a <italic>d</italic> value for the maximum translation and maximum rotation of each participant.<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ d=\sqrt{{\left({p}_1-{q}_1\right)}^2+{\left({p}_2-{q}_2\right)}^2+{\left({p}_3-{q}_3\right)}^2.} $$\end{document}</tex-math><mml:math id="M2"><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mtext>.</mml:mtext></mml:mrow></mml:msqrt></mml:math><graphic xlink:href="213_2014_3837_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p><p>Repeated measures ANOVAs showed no significant group by movement interaction effects in the Euclidean measures of maximum xyz rotation (<italic>F</italic> (df&#x02009;=&#x02009;4118)&#x02009;=&#x02009;2, <italic>p</italic>&#x02009;=&#x02009;0.14) or maximum xyz translation (<italic>F</italic>(df&#x02009;=&#x02009;4118)&#x02009;=&#x02009;1, <italic>p</italic>&#x02009;=&#x02009;0.58). Nevertheless, to eliminate any potential effects of non-significant variance in motion, these Euclidean motion parameters for maximum xyz translation and rotation were used as covariates in the fMRI analyses.</p><p>Within-group activations are reported in the supplementary results section and in supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref> and <xref rid="MOESM1" ref-type="media">S3</xref>.</p></sec></sec><sec id="Sec16"><title>Between-group differences between controls and patients under placebo</title><p>ANCOVA between controls and patients on placebo showed significant group differences in left middle/IFC, left OFC/superior temporal lobe (STL) reaching into putamen and globus pallidus and in left inferior parietal lobe (IPL). The hypothesised difference in right IFC was observed at a more lenient <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>) and confirmed by a region of interest analysis (Talairach coordinates (x;y;z)&#x02009;=&#x02009;54;7;26; BA 45; 10 voxels).<fig id="Fig1"><label>Fig. 1</label><caption><p>Between-group brain activation differences between controls and patients under placebo or fluoxetine for the contrast of successful stop with unsuccessful stop trials. <bold>a</bold> Axial sections showing the between-group ANCOVA comparison findings between controls and patients under placebo. Shown underneath are the statistical measures of BOLD response for each of the three groups for each of the brain regions that showed a significant group effect. <bold>b</bold> Axial sections for the between-group ANCOVA comparison between controls and patients under fluoxetine. Talairach <italic>z</italic> coordinates are indicated for slice distance (in mm) from the intercommissural line. The right side of the image corresponds to the right side of the brain</p></caption><graphic xlink:href="213_2014_3837_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>Brain activation differences between controls and patients on placebo or fluoxetine</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Post hoc group differences</th><th>Brain regions of activation differences</th><th>Brodmann area (BA)</th><th>Peak Talairach coordinates (x;y;z)</th><th>Voxels</th><th>Cluster <italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="6">Placebo</td></tr><tr><td>&#x02003;C &#x0003c; ASD</td><td>R inferior frontal cortex</td><td>44</td><td>54;15;26</td><td>16</td><td>0.03</td></tr><tr><td>&#x02003;C, ADHD &#x0003c; ASD</td><td>L inferior/middle frontal cortex</td><td>44/45/46/9</td><td>&#x02212;40;30;23</td><td>82</td><td>0.002</td></tr><tr><td>&#x02003;C, ASD &#x0003e; ADHD</td><td>L STL/OFC/putamen/globus pallidus</td><td>38/47/11/25</td><td>&#x02212;29;11;&#x02212;26</td><td>73</td><td>0.008</td></tr><tr><td>&#x02003;C &#x0003e; ADHD &#x0003e; ASD</td><td>L inferior parietal lobe</td><td>40</td><td>&#x02212;29;&#x02212;22;40</td><td>97</td><td>0.002</td></tr><tr><td colspan="6">Fluoxetine</td></tr><tr><td>&#x02003;C, ASD &#x0003e; ADHD</td><td>L + R pre-SMA/premotor/superior frontal cortex</td><td>6/8</td><td>&#x02212;11;4;63</td><td>203</td><td>0.0006</td></tr><tr><td>&#x02003;C &#x0003c; ADHD, ASD</td><td>SMA proper</td><td>6/8/9</td><td>&#x02212;4;&#x02212;11;50</td><td>42</td><td>0.007</td></tr><tr><td>&#x02003;ADHD &#x0003c; C &#x0003c; ASD</td><td>R inferior parietal lobe/angular gyrus</td><td>6</td><td>36;&#x02212;63;30</td><td>50</td><td>0.004</td></tr><tr><td>&#x02003;C, ASD &#x0003e; ADHD</td><td>L inferior parietal lobe/middle temporal</td><td>40/39</td><td>&#x02212;47;&#x02212;63;26</td><td>188</td><td>0.0002</td></tr><tr><td>&#x02003;C &#x0003c; ASD &#x0003c; ADHD</td><td>Precuneus</td><td>40/39</td><td>7;&#x02212;67;43</td><td>114</td><td>0.002</td></tr></tbody></table><table-wrap-foot><p>
<italic>STL</italic> superior temporal lobe, <italic>OFC</italic> Orbitofrontal cortex, <italic>SMA</italic> supplementary motor area</p></table-wrap-foot></table-wrap></p><p>Post hoc analyses showed that the group effect in right IFC was due to significantly increased activation in ASD relative to control boys (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.005) and trend-wise compared to ADHD boys (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.08). In left middle/IFC, ASD patients had significantly increased activation compared to both control and ADHD boys (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.005) who activated this region during failed inhibition and had a trend-wise reduction relative to controls (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.08). In left OFC/STL/basal ganglia both control and ASD boys, who did not differ from each other, showed increased activation relative to ADHD boys who activated this area during failed inhibition (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.005). Left IPL was significantly reduced in both patient groups relative to controls (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), with ASD patients activating this area significantly more during failed inhibition than ADHD (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p><p>To test whether group effects were related to task performance, we correlated all clusters with SSRT and omission errors, since they were lower in ADHD relative to controls and ASD. The (reduced) activation in left OFC/basal ganglia in ADHD was significantly negatively correlated with omission errors (<italic>r</italic>&#x02009;=&#x02009;&#x02212;0.5, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). No other correlations were significant.</p></sec><sec id="Sec17"><title>Between-group differences between controls and patients under fluoxetine</title><p>There were significant group differences in bilateral pre-SMA/superior frontal cortex, SMA proper, left IPL/middle temporal lobe, right IPL and precuneus (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Post hoc analyses showed that control and ASD boys, who did not differ, activated pre-SMA/superior frontal cortex significantly more during successful inhibition than ADHD boys who activated this cluster more during failed inhibition (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). SMA proper was significantly more activated in patients, who did not differ relative to controls, who activated this region more during failed inhibition (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). In bilateral IPL, controls and ASD boys had increased activation during successful inhibition relative to ADHD boys who activated this region more during failed inhibition (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). In right IPL, ASD boys also had increased activation relative to controls (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). In precuneus, ADHD boys showed significantly enhanced activation for successful inhibition relative to both ASD (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) and controls who activated this region during failed inhibition and differed relative to ASD (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). Correlations with behaviour showed that activation in pre-SMA/superior frontal cortex during successful inhibition was negatively correlated with SSRT in the ASD group (<italic>r</italic>&#x02009;=&#x02009;&#x02212;0.532, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). Activation in precuneus was negatively correlated with SSRT in the ADHD group (<italic>r</italic>&#x02009;=&#x02009;&#x02212;0.493, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p></sec><sec id="Sec18"><title>Effect size comparisons of case-control conditions to test for significant &#x0201c;normalisation&#x0201d; effects</title><p>To establish whether the group differences between controls and patients under each drug condition (ADHD/ASD under placebo versus controls; ADHD/ASD under fluoxetine versus controls) were significantly different, we directly compared the effect sizes (ES) of the group differences from the two case-control comparisons (Matthews and Altman <xref ref-type="bibr" rid="CR42">1996</xref>).</p><p>When comparing two effect sizes, the <italic>z</italic> test can evaluate the likelihood of whether they are significantly heterogeneous. The difference between the two effect sizes can be considered a normalized variable, where the standard error of the difference is a combination of the standard errors of the two comparisons. Based upon this, the probability of a type I error can be calculated using the formula: <italic>p</italic> (<italic>&#x003b1;</italic>)&#x02009;=&#x02009;(es<sub>1</sub>&#x02009;&#x02212;&#x02009;es<sub>2</sub>)/sqrt(se<sub>1</sub><sup>2</sup>&#x02009;+&#x02009;se<sub>2</sub><sup>2</sup>).</p><p>For the abnormalities in the ADHD patients, the effect sizes of the ADHD placebo-control contrast was not significantly different from the effect sizes of the ADHD fluoxetine-control comparison for left OFC (<italic>z</italic>&#x02009;=&#x02009;&#x02212;0.9, <italic>p</italic>&#x02009;=&#x02009;n.s.), right IFC (<italic>z</italic>&#x02009;=&#x02009;&#x02212;0.6; <italic>p</italic>&#x02009;=&#x02009;n.s.) or the left inferior parietal activation clusters (<italic>z</italic>&#x02009;=&#x02009;0.53, <italic>p</italic>&#x02009;=&#x02009;n.s.), suggesting that the normalisation effects in these clusters were not statistically significant.</p><p>For the abnormalities in the ASD patients, however, the effect sizes for the ASD placebo-control contrast were significantly different from the effect sizes for the ASD fluoxetine-control contrast for left IFC (<italic>z</italic>&#x02009;=&#x02009;2.8, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.005) and right IFC (<italic>z</italic>&#x02009;=&#x02009;&#x02212;2.5, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), both of which were enhanced under placebo but normalised under fluoxetine, and for left inferior parietal lobe, which was significantly reduced in ASD relative to controls under placebo, but enhanced under fluoxetine (<italic>z</italic>&#x02009;=&#x02009;2.3, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.02). The findings show that all normalisation effects in these clusters were statistically significant.</p></sec><sec id="Sec19"><title>Control for IQ</title><p>To assess the potential impact of IQ on case-control group differences, all analyses were repeated with IQ as a covariate. All clusters remained at a <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, apart from left OFC in the placebo between-group ANCOVA and right IPL in the fluoxetine between-group ANCOVA, which survived at a more lenient <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec><sec id="Sec20"><title>Within-patients group by medication interaction effects</title><p>ANCOVA analysis with group as dependent variable and drug as within-group variable showed a significant group by medication interaction effect in five clusters. (1) Fluoxetine reduced pre-SMA activation in ADHD boys, whereas it increased it in ASD boys during successful inhibition (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.005). (2) Fluoxetine increased activation in left OFC/STL/putamen/globus pallidus in ADHD during successful inhibition relative to placebo, but reduced it in ASD (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). (3) Both patient groups activated left IPL during failed inhibition under placebo, but ADHD boys activated this region more during failed inhibition and ASD boys more during successful inhibition under fluoxetine (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). (4) Right cerebellum activation was increased under fluoxetine in ADHD relative to placebo for successful inhibition, while ASD boys activated this area during failed inhibition under both placebo and fluoxetine (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). (5) At a more lenient <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, relative to placebo, fluoxetine increased activation in the hypothesised right IFC during successful inhibition in ADHD and decreased it in ASD (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). The same cluster was also confirmed by a region-of-interest analysis (Talairach coordinates (x;y;z)&#x02009;=&#x02009;51;4;30; BA 45; 7 voxels).<fig id="Fig2"><label>Fig. 2</label><caption><p>Within-patient group by medication interaction effects. Axial sections showing within-patient group by medication interaction effects for the contrast of successful stop-unsuccessful stop trials. Shown underneath are the statistical measures of BOLD response for each of the brain regions that showed a significant group by medication interaction effect within patients. Talairach <italic>z</italic> coordinates are indicated for slice distance (in mm) from the intercommissural line. The right side of the image corresponds to the right side of the brain</p></caption><graphic xlink:href="213_2014_3837_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab4"><label>Table 4</label><caption><p>Group by drug interaction effects within ADHD and ASD patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Brain regions of activation</th><th>Brodmann area (BA)</th><th>Peak Talairach coordinates (x;y;z)</th><th>Voxels</th><th>Cluster <italic>p</italic> value</th></tr></thead><tbody><tr><td>R inferior/middle frontal cortex</td><td>44/9</td><td>51;0;26</td><td>21</td><td>0.03</td></tr><tr><td>R pre-SMA/premotor/superior frontal cortex</td><td>6/8</td><td>&#x02212;7:33;56</td><td>1085</td><td>0.0003</td></tr><tr><td>L STL/OFC/putamen/globus pallidus</td><td>38/47/11/25</td><td>&#x02212;4;&#x02212;7;&#x02212;26</td><td>452</td><td>0.004</td></tr><tr><td>L inferior parietal/middle/STL/occipital lobe</td><td>39/40/22/19</td><td>&#x02212;43;&#x02212;67;30</td><td>237</td><td>0.008</td></tr><tr><td>R cerebellum</td><td/><td>22;&#x02212;41;&#x02212;17</td><td>139</td><td>0.0005</td></tr></tbody></table><table-wrap-foot><p>
<italic>STL</italic> superior temporal lobe, <italic>OFC</italic> orbitofrontal cortex, <italic>SMA</italic> supplementary motor area</p></table-wrap-foot></table-wrap></p><p>No significant correlations with performance were observed. All findings remained when IQ was covaried for.</p></sec></sec><sec id="Sec21" sec-type="discussion"><title>Discussion</title><p>The findings reveal opposite brain dysfunction patterns in inhibitory brain regions in ADHD and ASD as well as opposite disorder-dissociated modulation effects of fluoxetine on these neurofunctional abnormalities. Relative to controls, ADHD patients showed reduced left OFC/basal ganglia activation, whereas ASD patients showed enhanced bilateral ventrolateral prefrontal activation relative to ADHD and controls. Fluoxetine normalized these disorder-dissociated brain abnormalities relative to controls, via disorder-dissociated opposite effects within patients: fluoxetine enhanced the abnormally reduced OFC/basal ganglia activation in ADHD, but reduced it in ASD. In contrast, it reduced the abnormally enhanced IFC activation in ASD, but enhanced it in ADHD. However, rigorous testing for the significance of these normalisation effects showed that these were only significant for the abnormality clusters in ASD. Furthermore, fluoxetine also had opposite disorder-dissociated effects on other inhibition areas such as pre-SMA and cerebellum: these were, respectively, enhanced (SMA) and reduced (cerebellum) in ADHD with fluoxetine relative to placebo, but reduced (SMA) and enhanced (cerebellum) in ASD.</p><p>The finding of disorder-specific increased activation in ASD relative to controls and ADHD in the left and right (trend-wise significant relative to ADHD) IFC extends our previous finding of increased left IFC activation in young adults with Asperger's syndrome during a go/no-go task (Schmitz et al. <xref ref-type="bibr" rid="CR68">2006</xref>) by demonstrating disorder-specificity relative to ADHD. Predominantly, the right (Chambers et al. <xref ref-type="bibr" rid="CR11">2009</xref>; Rubia et al. <xref ref-type="bibr" rid="CR64">2003</xref>) but also left IFC (Hampshire et al. <xref ref-type="bibr" rid="CR27">2010</xref>; Rubia et al. <xref ref-type="bibr" rid="CR60">2011</xref>; Rubia et al. <xref ref-type="bibr" rid="CR63">2001</xref>; Rubia et al. <xref ref-type="bibr" rid="CR66">2007</xref>) are crucial areas mediating response inhibition and ASD patients may have needed to recruit these areas more for comparable task performance. ADHD patients had no underactivation in these areas relative to controls, unlike observed previously (Cubillo et al. <xref ref-type="bibr" rid="CR17">2014</xref>; Hart et al. <xref ref-type="bibr" rid="CR29">2013</xref>; Rubia <xref ref-type="bibr" rid="CR58">2011</xref>; Rubia et al. <xref ref-type="bibr" rid="CR62">1999</xref>; Rubia et al. <xref ref-type="bibr" rid="CR65">2005b</xref>), but relative to ASD. This, and the lack of a significant difference between controls and ADHD boys in SSRT may be due to long-term effects of stimulant medication, which has been associated with more normal prefrontal and striatal function (Hart et al. <xref ref-type="bibr" rid="CR28">2012</xref>; Hart et al. <xref ref-type="bibr" rid="CR29">2013</xref>; Rubia et al. <xref ref-type="bibr" rid="CR59">2014</xref>), as 11 of the ADHD boys were on chronic methylphenidate medication, even if taken off medication prior to the scan. It is also interesting to note that the enhanced omission errors which were observed in ADHD patients relative to both control and ASD boys under placebo were correlated with reduced IFC-striatal activation under placebo. It has been suggested that omission errors are indicative of an alternative strategy that ADHD boys may employ to decrease their number of failed inhibitions (Tannock et al. <xref ref-type="bibr" rid="CR73">1989</xref>). Therefore, although there was no behavioural evidence for poor inhibitory performance using the inhibitory measure of the SSRT, there were significant behavioural differences in omission errors in ADHD patients under placebo. The differences correlated with the neurofunctional deficits and were no longer observed under fluoxetine. The disorder-exclusive deficits in ADHD adolescents in the left OFC/basal ganglia relative to controls extend prior findings of OFC-striatal deficits in ADHD (Cubillo et al. <xref ref-type="bibr" rid="CR17">2014</xref>; Hart et al. <xref ref-type="bibr" rid="CR29">2013</xref>; Rubia <xref ref-type="bibr" rid="CR58">2011</xref>; Rubia et al. <xref ref-type="bibr" rid="CR62">1999</xref>; Rubia et al. <xref ref-type="bibr" rid="CR65">2005b</xref>; Rubia et al. <xref ref-type="bibr" rid="CR59">2014</xref>). Our results therefore show disorder-dissociated frontal lobe dysfunctions in ADHD and ASD boys during inhibition relative to controls: with ASD patients showing significantly enhanced bilateral IFC activation and ADHD boys showing significantly reduced OFC/basal ganglia activation, which furthermore correlated with their enhanced omission errors during task performance.</p><p>Fluoxetine normalized all disorder-dissociated frontal brain dysfunctions due to opposite modulation effects in both disorders, which were, however, only significant in the ASD group. Fluoxetine significantly reduced bilateral OFC activation in the ASD group but enhanced it in ADHD. Under fluoxetine, ADHD patients also no longer showed enhanced omission errors, which were reduced under placebo and correlated with the OFC deficits. Fluoxetine also had an opposite up/downregulation effect on another key inhibition region, the pre-SMA: this was upregulated in ASD and hence increased relative to controls and ADHD, but downregulated in ADHD and hence reduced relative to controls and ASD. The upregulation effect of fluoxetine on right IFC and left OFC-striatal regions in ADHD extends prior evidence on SE agonist modulation of these areas in healthy adults during inhibitory control (Del-Ben et al. <xref ref-type="bibr" rid="CR18">2005</xref>) to the ADHD population. Most intriguing, however, are the consistently opposite reduction effects of fluoxetine on these frontal activations in the ASD group. Opposite activation effects could possibly reflect group differences in baseline SE levels, as evidenced by lower platelet SE levels in ADHD children compared to controls (Spivak et al. <xref ref-type="bibr" rid="CR72">1999</xref>), and increased baseline platelet, blood and prefrontal SE levels in 30&#x000a0;% of individuals with ASD relative to controls (Hranilovic et al. <xref ref-type="bibr" rid="CR31">2007</xref>; Mulder et al. <xref ref-type="bibr" rid="CR43">2004</xref>; Nakamura et al. <xref ref-type="bibr" rid="CR45">2010</xref>; Piven et al. <xref ref-type="bibr" rid="CR51">1991</xref>). In addition, ASD patients have abnormal 5-HT synthesis (Chugani et al. <xref ref-type="bibr" rid="CR12">1997</xref>), 5-HT transporter (Makkonen et al. <xref ref-type="bibr" rid="CR41">2008</xref>; Nakamura et al. <xref ref-type="bibr" rid="CR45">2010</xref>) and 5-HT<sub>2A</sub> receptor binding (Murphy et al. <xref ref-type="bibr" rid="CR44">2006</xref>). Therefore, fluoxetine may increase the low SE baseline of children with ADHD to normal levels, leading to normalized activation in fronto-striatal areas. Whereas in children with ASD, the increase in SE in an already hyperserotonemic system may activate a negative feedback mechanism via activation of 5-HT<sub>1A</sub> autoreceptors (Sibley et al. <xref ref-type="bibr" rid="CR69">2007</xref>), leading to a decrease in SE and in fronto-striatal activation.</p><p>Despite significant modulation effects on brain activation, fluoxetine had no effect on inhibitory performance. However, the enhanced omission errors that were observed in ADHD patients under placebo relative to controls were no longer significant under fluoxetine. Furthermore, it is well documented that brain function is more sensitive to pharmacological manipulations than inhibitory performance (Cubillo et al. <xref ref-type="bibr" rid="CR17">2014</xref>; Rubia et al. <xref ref-type="bibr" rid="CR60">2011</xref>; Rubia et al. <xref ref-type="bibr" rid="CR61">2005a</xref>). In addition, one of the upregulated regions in ASD in a key inhibitory area, the pre-SMA, was correlated with SSRT, suggesting a relationship between activation changes and inhibitory performance.</p><p>The strengths of this study are carefully selected and non-comorbid patient groups who had no psychiatric comorbidities and, in the case of the ASD group, were medication-na&#x000ef;ve. A limitation of this study is that for ethical and financial reasons, the control group was scanned only once, while patients were scanned twice which could have accounted for the lack of performance differences. The significantly lower IQ in the ADHD compared to the other two groups is another limitation. However, covariance analysis showed that the findings were not affected by IQ. Furthermore, stop task performance has been shown to be independent of IQ (Friedman et al. <xref ref-type="bibr" rid="CR22">2006</xref>). Lastly, while the contrast of successful and unsuccessful stop trials controls for the attentional oddball effect of the low frequency of stop stimuli, it may be over-conservative, as during unsuccessful stop trials subjects may also attempt, but not achieve to inhibit.</p></sec><sec id="Sec22" sec-type="conclusion"><title>Conclusions</title><p>To summarise, ADHD and ASD patients showed opposite brain activation abnormalities relative to controls: ADHD boys showed reduced while ASD boys enhanced frontal activation. Importantly, fluoxetine had a disorder-dissociated opposite effect on frontal brain dysfunctions, enhancing frontal activation in ADHD and reducing it in ASD which could suggest differential underlying SE baseline levels in the two disorders.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec23"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="213_2014_3837_MOESM1_ESM.docx"><label>ESM 1</label><caption><p>(DOCX 214&#x000a0;kb)</p></caption></media></supplementary-material></sec></sec></body><back><ack><p>This study and Dr. Andy Simmonds were supported by the UK Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) for Mental Health at South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, King&#x02019;s College London. The research leading to these results has also received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n&#x000b0; 115300, resources of which are composed of financial contribution from the European Union&#x02019;s Seventh Framework Programme (FP7/2007 - 2013) and EFPIA companies' in kind contribution.</p><sec id="FPar1"><title>Funding</title><p>Katya Rubia has received a funding from Lilly for another project and speaker&#x02019;s honoraria from Lilly, Shire and Novartis. Michael Brammer is a consultant for P1vital, Ltd, Oxford, UK.</p></sec><sec id="FPar2"><title>Conflict of interest</title><p>The other authors have no conflict of interests to declare.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alderson</surname><given-names>R</given-names></name><name><surname>Rapport</surname><given-names>M</given-names></name><name><surname>Kofler</surname><given-names>M</given-names></name></person-group><article-title>Attention-deficit/hyperactivity disorder and behavioral inhibition: a meta-analytic review of the stop-signal paradigm</article-title><source>J Abnorm Child Psychol</source><year>2007</year><volume>35</volume><issue>5</issue><fpage>745</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1007/s10802-007-9131-6</pub-id><pub-id pub-id-type="pmid">17668315</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group><source>Diagnostic and Statistical Manual of Mental Disorders</source><year>2000</year><edition>4</edition><publisher-loc>Washington</publisher-loc><publisher-name>American Psychiatric Association</publisher-name></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>IM</given-names></name><name><surname>McKie</surname><given-names>S</given-names></name><name><surname>Elliott</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>SR</given-names></name><name><surname>Deakin</surname><given-names>JFW</given-names></name></person-group><article-title>Assessing human 5-HT function in vivo with pharmacoMRI</article-title><source>Neuropharmacology</source><year>2008</year><volume>55</volume><issue>6</issue><fpage>1029</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.06.029</pub-id><pub-id pub-id-type="pmid">18621068</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrickman</surname><given-names>L</given-names></name><name><surname>Noyes</surname><given-names>R</given-names></name><name><surname>Kuperman</surname><given-names>S</given-names></name><name><surname>Schumacher</surname><given-names>E</given-names></name><name><surname>Verda</surname><given-names>M</given-names></name></person-group><article-title>Treatment of ADHD with fluoxetine&#x02014;a preliminary trial</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>1991</year><volume>30</volume><issue>5</issue><fpage>762</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">1938791</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brammer</surname><given-names>MJ</given-names></name><name><surname>Bullmore</surname><given-names>ET</given-names></name><name><surname>Simmons</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>SCR</given-names></name><name><surname>Grasby</surname><given-names>PM</given-names></name><name><surname>Howard</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Generic brain activation mapping in functional magnetic resonance imaging: a nonparametric approach</article-title><source>Magn Reson Imaging</source><year>1997</year><volume>15</volume><issue>7</issue><fpage>763</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1016/S0730-725X(97)00135-5</pub-id><pub-id pub-id-type="pmid">9309607</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bridgett</surname><given-names>DJ</given-names></name><name><surname>Walker</surname><given-names>ME</given-names></name></person-group><article-title>Intellectual functioning in adults with ADHD: a meta-analytic examination of full scale IQ differences between adults with and without ADHD</article-title><source>Psychol Assess</source><year>2006</year><volume>18</volume><issue>1</issue><fpage>1</fpage><pub-id pub-id-type="doi">10.1037/1040-3590.18.1.1</pub-id><pub-id pub-id-type="pmid">16594807</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullmore</surname><given-names>E</given-names></name><name><surname>Brammer</surname><given-names>M</given-names></name><name><surname>Rabe-Hesketh</surname><given-names>S</given-names></name><name><surname>Curtis</surname><given-names>V</given-names></name><name><surname>Morris</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name><etal/></person-group><article-title>Methods for diagnosis and treatment of stimulus-correlated motion in generic brain activation studies using fMRI</article-title><source>Hum Brain Mapp</source><year>1999</year><volume>7</volume><issue>1</issue><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0193(1999)7:1&#x0003c;38::AID-HBM4&#x0003e;3.0.CO;2-Q</pub-id><pub-id pub-id-type="pmid">9882089</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullmore</surname><given-names>E</given-names></name><name><surname>Long</surname><given-names>C</given-names></name><name><surname>Suckling</surname><given-names>J</given-names></name><name><surname>Fadili</surname><given-names>J</given-names></name><name><surname>Calvert</surname><given-names>G</given-names></name><name><surname>Zelaya</surname><given-names>F</given-names></name><etal/></person-group><article-title>Colored noise and computational inference in neurophysiological (fMRI) time series analysis: resampling methods in time and wavelet domains</article-title><source>Hum Brain Mapp</source><year>2001</year><volume>12</volume><issue>2</issue><fpage>61</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1002/1097-0193(200102)12:2&#x0003c;61::AID-HBM1004&#x0003e;3.0.CO;2-W</pub-id><pub-id pub-id-type="pmid">11169871</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullmore</surname><given-names>ET</given-names></name><name><surname>Suckling</surname><given-names>J</given-names></name><name><surname>Overmeyer</surname><given-names>S</given-names></name><name><surname>Rabe-Hesketh</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>E</given-names></name><name><surname>Brammer</surname><given-names>MJ</given-names></name></person-group><article-title>Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain</article-title><source>IEEE Trans Med Imaging</source><year>1999</year><volume>18</volume><issue>1</issue><fpage>32</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1109/42.750253</pub-id><pub-id pub-id-type="pmid">10193695</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>SR</given-names></name><name><surname>Muller</surname><given-names>U</given-names></name><name><surname>Blackwell</surname><given-names>AD</given-names></name><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name></person-group><article-title>Neurochemical modulation of response inhibition and probabilistic learning in humans</article-title><source>Science</source><year>2006</year><volume>311</volume><issue>5762</issue><fpage>861</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1126/science.1121218</pub-id><pub-id pub-id-type="pmid">16469930</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>CD</given-names></name><name><surname>Garavan</surname><given-names>H</given-names></name><name><surname>Bellgrove</surname><given-names>MA</given-names></name></person-group><article-title>Insights into the neural basis of response inhibition from cognitive and clinical neuroscience</article-title><source>Neurosci Biobehav Rev</source><year>2009</year><volume>33</volume><issue>5</issue><fpage>631</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2008.08.016</pub-id><pub-id pub-id-type="pmid">18835296</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chugani</surname><given-names>DC</given-names></name><name><surname>Muzik</surname><given-names>O</given-names></name><name><surname>Rothermel</surname><given-names>R</given-names></name><name><surname>Behen</surname><given-names>M</given-names></name><name><surname>Chakraborty</surname><given-names>P</given-names></name><name><surname>Mangner</surname><given-names>T</given-names></name><etal/></person-group><article-title>Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys</article-title><source>Ann Neurol</source><year>1997</year><volume>42</volume><issue>4</issue><fpage>666</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1002/ana.410420420</pub-id><pub-id pub-id-type="pmid">9382481</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conners</surname><given-names>CK</given-names></name><name><surname>Sitarenios</surname><given-names>G</given-names></name><name><surname>Parker</surname><given-names>JDA</given-names></name><name><surname>Epstein</surname><given-names>JN</given-names></name></person-group><article-title>Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity</article-title><source>J Abnorm Child Psychol</source><year>1998</year><volume>26</volume><issue>4</issue><fpage>279</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1023/A:1022606501530</pub-id><pub-id pub-id-type="pmid">9700520</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corbett</surname><given-names>BA</given-names></name><name><surname>Constantine</surname><given-names>LJ</given-names></name><name><surname>Hendren</surname><given-names>R</given-names></name><name><surname>Rocke</surname><given-names>D</given-names></name><name><surname>Ozonoff</surname><given-names>S</given-names></name></person-group><article-title>Examining executive functioning in children with autism spectrum disorder, attention deficit hyperactivity disorder and typical development</article-title><source>Psychiatry Res</source><year>2009</year><volume>166</volume><issue>2&#x02013;3</issue><fpage>210</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2008.02.005</pub-id><pub-id pub-id-type="pmid">19285351</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortese</surname><given-names>S</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>Chabernaud</surname><given-names>C</given-names></name><name><surname>Proal</surname><given-names>E</given-names></name><name><surname>Di Martino</surname><given-names>A</given-names></name><name><surname>Milham</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies</article-title><source>Am J Psychiatry</source><year>2012</year><volume>169</volume><issue>10</issue><fpage>1038</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2012.11101521</pub-id><pub-id pub-id-type="pmid">22983386</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cubillo</surname><given-names>A</given-names></name><name><surname>Halari</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>E</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name></person-group><article-title>A review of fronto-striatal and fronto-cortical brain abnormalities in children and adults with attention deficit hyperactivity disorder (ADHD) and new evidence for dysfunction in adults with ADHD during motivation and attention</article-title><source>Cortex</source><year>2012</year><volume>48</volume><issue>2</issue><fpage>194</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.cortex.2011.04.007</pub-id><pub-id pub-id-type="pmid">21575934</pub-id></element-citation></ref><ref id="CR17"><mixed-citation publication-type="other">Cubillo A, Smith A, Barrett N, Giampetro V, Brammer M, Simmons A et al. (2014) Shared and drug specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys. Cerebal Cortex 24(1):174&#x02013;185</mixed-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del-Ben</surname><given-names>CM</given-names></name><name><surname>Deakin</surname><given-names>JFW</given-names></name><name><surname>McKie</surname><given-names>S</given-names></name><name><surname>Delvai</surname><given-names>NA</given-names></name><name><surname>Williams</surname><given-names>SR</given-names></name><name><surname>Elliott</surname><given-names>R</given-names></name><etal/></person-group><article-title>The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an fMRI study</article-title><source>Neuropsychopharmacology</source><year>2005</year><volume>30</volume><issue>9</issue><fpage>1724</fpage><lpage>1734</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300728</pub-id><pub-id pub-id-type="pmid">15827569</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLong</surname><given-names>GR</given-names></name><name><surname>Ritch</surname><given-names>CR</given-names></name><name><surname>Burch</surname><given-names>S</given-names></name></person-group><article-title>Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement</article-title><source>Dev Med Child Neurol</source><year>2002</year><volume>44</volume><issue>10</issue><fpage>652</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.2002.tb00266.x</pub-id><pub-id pub-id-type="pmid">12418789</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLong</surname><given-names>GR</given-names></name><name><surname>Teague</surname><given-names>LA</given-names></name><name><surname>Kamran</surname><given-names>MM</given-names></name></person-group><article-title>Effects of fluoxetine treatment in young children with idiopathic autism</article-title><source>Dev Med Child Neurol</source><year>1998</year><volume>40</volume><issue>8</issue><fpage>551</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.1998.tb15414.x</pub-id><pub-id pub-id-type="pmid">9746008</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>M</given-names></name><name><surname>Francis</surname><given-names>DJ</given-names></name><name><surname>Cirino</surname><given-names>PT</given-names></name><name><surname>Schachar</surname><given-names>R</given-names></name><name><surname>Barnes</surname><given-names>MA</given-names></name><name><surname>Fletcher</surname><given-names>JM</given-names></name></person-group><article-title>Why IQ is not a covariate in cognitive studies of neurodevelopmental disorders</article-title><source>J Int Neuropsychol Soc</source><year>2009</year><volume>15</volume><issue>3</issue><fpage>331</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1017/S1355617709090481</pub-id><pub-id pub-id-type="pmid">19402919</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>NP</given-names></name><name><surname>Miyake</surname><given-names>A</given-names></name><name><surname>Corley</surname><given-names>RP</given-names></name><name><surname>Young</surname><given-names>SE</given-names></name><name><surname>DeFries</surname><given-names>JC</given-names></name><name><surname>Hewitt</surname><given-names>JK</given-names></name></person-group><article-title>Not all executive functions are related to intelligence</article-title><source>Psychol Sci</source><year>2006</year><volume>17</volume><issue>2</issue><fpage>172</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1111/j.1467-9280.2006.01681.x</pub-id><pub-id pub-id-type="pmid">16466426</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gammon</surname><given-names>GD</given-names></name><name><surname>Brown</surname><given-names>TE</given-names></name></person-group><article-title>Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder</article-title><source>J Child Adolesc Psychopharmacol</source><year>1993</year><volume>3</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1089/cap.1993.3.1</pub-id><pub-id pub-id-type="pmid">19630593</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geurts</surname><given-names>HM</given-names></name><name><surname>Vertie</surname><given-names>S</given-names></name><name><surname>Oosterlaan</surname><given-names>J</given-names></name><name><surname>Roeyers</surname><given-names>H</given-names></name><name><surname>Sergeant</surname><given-names>JA</given-names></name></person-group><article-title>How specific are executive functioning deficits in attention deficit hyperactivity disorder and autism?</article-title><source>J Child Psychol Psychiatry</source><year>2004</year><volume>45</volume><issue>4</issue><fpage>836</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1111/j.1469-7610.2004.00276.x</pub-id><pub-id pub-id-type="pmid">15056314</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>DP</given-names></name><name><surname>Murray</surname><given-names>R</given-names></name></person-group><source>The Maudsley Handbook of Practical Psychiatry</source><year>2006</year><publisher-loc>New York</publisher-loc><publisher-name>Oxford University Press</publisher-name></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>R</given-names></name><name><surname>Scott</surname><given-names>S</given-names></name></person-group><article-title>Comparing the strengths and difficulties questionnaire and the child behavior checklist: is small beautiful?</article-title><source>J Abnorm Child Psychol</source><year>1999</year><volume>27</volume><issue>1</issue><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1023/A:1022658222914</pub-id><pub-id pub-id-type="pmid">10197403</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampshire</surname><given-names>A</given-names></name><name><surname>Chamberlain</surname><given-names>SR</given-names></name><name><surname>Monti</surname><given-names>MM</given-names></name><name><surname>Duncan</surname><given-names>J</given-names></name><name><surname>Owen</surname><given-names>AM</given-names></name></person-group><article-title>The role of the right inferior frontal gyrus: inhibition and attentional control</article-title><source>Neuroimage</source><year>2010</year><volume>50</volume><issue>3</issue><fpage>1313</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.12.109</pub-id><pub-id pub-id-type="pmid">20056157</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>H</given-names></name><name><surname>Radua</surname><given-names>J</given-names></name><name><surname>Mataix-Cols</surname><given-names>D</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name></person-group><article-title>Meta-analysis of fMRI studies of timing in attention-deficit hyperactivity disorder (ADHD)</article-title><source>Neurosci Biobehav Rev</source><year>2012</year><volume>36</volume><issue>10</issue><fpage>2248</fpage><lpage>2256</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2012.08.003</pub-id><pub-id pub-id-type="pmid">22922163</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>H</given-names></name><name><surname>Radua</surname><given-names>J</given-names></name><name><surname>Nakao</surname><given-names>T</given-names></name><name><surname>Mataix-Cols</surname><given-names>D</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name></person-group><article-title>Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects</article-title><source>JAMA Psychiatry</source><year>2013</year><volume>70</volume><issue>2</issue><fpage>185</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.277</pub-id><pub-id pub-id-type="pmid">23247506</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollander</surname><given-names>E</given-names></name><name><surname>Phillips</surname><given-names>A</given-names></name><name><surname>Chaplin</surname><given-names>W</given-names></name><name><surname>Zagursky</surname><given-names>K</given-names></name><name><surname>Novotny</surname><given-names>S</given-names></name><name><surname>Wasserman</surname><given-names>S</given-names></name><etal/></person-group><article-title>A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism</article-title><source>Neuropsychopharmacology</source><year>2005</year><volume>30</volume><issue>3</issue><fpage>582</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300627</pub-id><pub-id pub-id-type="pmid">15602505</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hranilovic</surname><given-names>D</given-names></name><name><surname>Bujas-Petkovic</surname><given-names>Z</given-names></name><name><surname>Vragovic</surname><given-names>R</given-names></name><name><surname>Vuk</surname><given-names>T</given-names></name><name><surname>Hock</surname><given-names>K</given-names></name><name><surname>Jernej</surname><given-names>B</given-names></name></person-group><article-title>Hyperserotonemia in adults with autistic disorder</article-title><source>J Autism Dev Disord</source><year>2007</year><volume>37</volume><fpage>1934</fpage><lpage>1940</lpage><pub-id pub-id-type="doi">10.1007/s10803-006-0324-6</pub-id><pub-id pub-id-type="pmid">17165147</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kana</surname><given-names>RK</given-names></name><name><surname>Keller</surname><given-names>TA</given-names></name><name><surname>Minshew</surname><given-names>NJ</given-names></name><name><surname>Just</surname><given-names>MA</given-names></name></person-group><article-title>Inhibitory control in high-functioning autism: decreased activation and underconnectivity in inhibition networks</article-title><source>Biol Psychiatry</source><year>2007</year><volume>62</volume><issue>3</issue><fpage>198</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2006.08.004</pub-id><pub-id pub-id-type="pmid">17137558</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>BH</given-names></name><name><surname>Hollander</surname><given-names>E</given-names></name><name><surname>Sikich</surname><given-names>L</given-names></name><name><surname>McCracken</surname><given-names>JT</given-names></name><name><surname>Scahill</surname><given-names>L</given-names></name><name><surname>Bregman</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior citalopram ineffective in children with autism</article-title><source>Arch Gen Psychiatry</source><year>2009</year><volume>66</volume><issue>6</issue><fpage>583</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2009.30</pub-id><pub-id pub-id-type="pmid">19487623</pub-id></element-citation></ref><ref id="CR34"><mixed-citation publication-type="other">Lamar M, Craig M, Daly EM, Cutter WJ, Tang C, Brammer M et al. (2012) Acute tryptophan depletion promotes an anterior-to-posterior fMRI activation shift during task switching in older adults. Hum Brain Mapp In Press</mixed-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamar</surname><given-names>M</given-names></name><name><surname>Cutter</surname><given-names>WJ</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Brammer</surname><given-names>M</given-names></name><name><surname>Daly</surname><given-names>EM</given-names></name><name><surname>Craig</surname><given-names>MC</given-names></name><etal/></person-group><article-title>5-HT, prefrontal function and aging: fMRI of inhibition and acute tryptophan depletion</article-title><source>Neurobiol Aging</source><year>2009</year><volume>30</volume><issue>7</issue><fpage>1135</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2007.09.013</pub-id><pub-id pub-id-type="pmid">18061310</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langen</surname><given-names>M</given-names></name><name><surname>Durston</surname><given-names>S</given-names></name><name><surname>Kas</surname><given-names>MJH</given-names></name><name><surname>van Engeland</surname><given-names>H</given-names></name><name><surname>Staal</surname><given-names>WG</given-names></name></person-group><article-title>The neurobiology of repetitive behavior: &#x02026; and men</article-title><source>Neurosci Biobehav Rev</source><year>2011</year><volume>35</volume><issue>3</issue><fpage>356</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2010.02.005</pub-id><pub-id pub-id-type="pmid">20153769</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipsyzc</surname><given-names>J</given-names></name><name><surname>Schachar</surname><given-names>R</given-names></name></person-group><article-title>Inhibitory control and psychopathology: a meta-analysis of studies using the stop signal task</article-title><source>J Int Neuropsychol Soc</source><year>2010</year><volume>16</volume><issue>06</issue><fpage>1064</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1017/S1355617710000895</pub-id><pub-id pub-id-type="pmid">20719043</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>GD</given-names></name><name><surname>Schachar</surname><given-names>RJ</given-names></name><name><surname>Tannock</surname><given-names>R</given-names></name></person-group><article-title>Impulsivity and inhibitory control</article-title><source>Psychol Sci</source><year>1997</year><volume>8</volume><issue>1</issue><fpage>60</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1111/j.1467-9280.1997.tb00545.x</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>C</given-names></name><name><surname>Risi</surname><given-names>S</given-names></name><name><surname>Lambrecht</surname><given-names>L</given-names></name><name><surname>Cook</surname><given-names>EH</given-names></name><name><surname>Leventhal</surname><given-names>BL</given-names></name><name><surname>DiLavore</surname><given-names>PC</given-names></name><etal/></person-group><article-title>The autism diagnostic observation schedule generic: a standard measure of social and communication deficits associated with the spectrum of autism</article-title><source>J Autism Dev Disord</source><year>2000</year><volume>30</volume><issue>3</issue><fpage>205</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1023/A:1005592401947</pub-id><pub-id pub-id-type="pmid">11055457</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>C</given-names></name><name><surname>Rutter</surname><given-names>M</given-names></name><name><surname>Couteur</surname><given-names>A</given-names></name></person-group><article-title>Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders</article-title><source>J Autism Dev Disord</source><year>1994</year><volume>24</volume><issue>5</issue><fpage>659</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1007/BF02172145</pub-id><pub-id pub-id-type="pmid">7814313</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makkonen</surname><given-names>I</given-names></name><name><surname>Riikonen</surname><given-names>R</given-names></name><name><surname>Kokki</surname><given-names>H</given-names></name><name><surname>Airaksinen</surname><given-names>MM</given-names></name><name><surname>Kuikka</surname><given-names>JT</given-names></name></person-group><article-title>Serotonin and dopamine transporter binding in children with autism determined by SPECT</article-title><source>Dev Med Child Neurol</source><year>2008</year><volume>50</volume><issue>8</issue><fpage>593</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.2008.03027.x</pub-id><pub-id pub-id-type="pmid">18754896</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>JN</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Statistics notes. Interaction 2: compare effect sizes not <italic>P</italic> values</article-title><source>BMJ</source><year>1996</year><volume>313</volume><fpage>808</fpage><pub-id pub-id-type="doi">10.1136/bmj.313.7060.808</pub-id><pub-id pub-id-type="pmid">8842080</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulder</surname><given-names>EJ</given-names></name><name><surname>Anderson</surname><given-names>GM</given-names></name><name><surname>Kema</surname><given-names>IP</given-names></name><name><surname>de Bildt</surname><given-names>A</given-names></name><name><surname>van Lang</surname><given-names>NDJ</given-names></name><name><surname>den Boer</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Platelet serotonin levels in pervasive developmental disorders and mental retardation: diagnostic group differences, within-group distribution, and behavioral correlates</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2004</year><volume>43</volume><issue>4</issue><fpage>491</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1097/00004583-200404000-00016</pub-id><pub-id pub-id-type="pmid">15187810</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>DGM</given-names></name><name><surname>Daly</surname><given-names>E</given-names></name><name><surname>Schmitz</surname><given-names>N</given-names></name><name><surname>Toal</surname><given-names>F</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Curran</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger&#x02019;s syndrome: an in vivo SPECT study</article-title><source>Am J Psychiatry</source><year>2006</year><volume>163</volume><issue>5</issue><fpage>934</fpage><lpage>936</lpage><pub-id pub-id-type="pmid">16648340</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Sekine</surname><given-names>Y</given-names></name><name><surname>Ouchi</surname><given-names>Y</given-names></name><name><surname>Tsujii</surname><given-names>M</given-names></name><name><surname>Yoshikawa</surname><given-names>E</given-names></name><name><surname>Futatsubashi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Brain serotonin and dopamine transporter bindings in adults with high-functioning autism</article-title><source>Arch Gen Psychiatry</source><year>2010</year><volume>67</volume><issue>1</issue><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2009.137</pub-id><pub-id pub-id-type="pmid">20048223</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oades</surname><given-names>RD</given-names></name></person-group><article-title>Role of the serotonin system in ADHD: treatment implications</article-title><source>Expert Rev Neurother</source><year>2007</year><volume>7</volume><issue>10</issue><fpage>1357</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1586/14737175.7.10.1357</pub-id><pub-id pub-id-type="pmid">17939772</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldfield</surname><given-names>RC</given-names></name></person-group><article-title>The assessment and analysis of handedness: the Edinburgh inventory</article-title><source>Neuropsychologia</source><year>1971</year><volume>9</volume><issue>1</issue><fpage>97</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/0028-3932(71)90067-4</pub-id><pub-id pub-id-type="pmid">5146491</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozonoff</surname><given-names>S</given-names></name><name><surname>Strayer</surname><given-names>DL</given-names></name></person-group><article-title>Inhibitory function in nonretarded children with autism</article-title><source>J Autism Dev Disord</source><year>1997</year><volume>27</volume><issue>1</issue><fpage>59</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1023/A:1025821222046</pub-id><pub-id pub-id-type="pmid">9018582</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauls</surname><given-names>AM</given-names></name><name><surname>O&#x02019;Daly</surname><given-names>OG</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Riedel</surname><given-names>WJ</given-names></name><name><surname>Williams</surname><given-names>SC</given-names></name><name><surname>Mehta</surname><given-names>MA</given-names></name></person-group><article-title>Methylphenidate effects on prefrontal functioning during attentional-capture and response inhibition</article-title><source>Biol Psychiatry</source><year>2012</year><volume>72</volume><issue>2</issue><fpage>142</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2012.03.028</pub-id><pub-id pub-id-type="pmid">22552046</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauls</surname><given-names>AM</given-names></name><name><surname>O&#x02019;Daly</surname><given-names>OG</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Riedel</surname><given-names>WJ</given-names></name><name><surname>Williams</surname><given-names>SC</given-names></name><name><surname>Mehta</surname><given-names>MA</given-names></name></person-group><article-title>Methylphenidate effects on prefrontal functioning during attentional-capture and response inhibition</article-title><source>Biol Psychiatry</source><year>2012</year><volume>72</volume><fpage>142</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2012.03.028</pub-id><pub-id pub-id-type="pmid">22552046</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piven</surname><given-names>J</given-names></name><name><surname>Tsai</surname><given-names>G</given-names></name><name><surname>Nehme</surname><given-names>E</given-names></name><name><surname>Coyle</surname><given-names>JT</given-names></name><name><surname>Chase</surname><given-names>GA</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name></person-group><article-title>Platelet serotonin, a possible marker for familial autism</article-title><source>J Autism Dev Disord</source><year>1991</year><volume>21</volume><issue>1</issue><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1007/BF02206997</pub-id><pub-id pub-id-type="pmid">2037549</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintana</surname><given-names>H</given-names></name><name><surname>Butterbaugh</surname><given-names>GJ</given-names></name><name><surname>Purnell</surname><given-names>W</given-names></name><name><surname>Layman</surname><given-names>AK</given-names></name></person-group><article-title>Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents</article-title><source>Child Psychiatry Hum Dev</source><year>2007</year><volume>37</volume><issue>3</issue><fpage>241</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1007/s10578-006-0032-7</pub-id><pub-id pub-id-type="pmid">17103304</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raymaekers</surname><given-names>R</given-names></name><name><surname>Antrop</surname><given-names>I</given-names></name><name><surname>van der Meere</surname><given-names>JJ</given-names></name><name><surname>Wiersema</surname><given-names>JR</given-names></name><name><surname>Roeyers</surname><given-names>H</given-names></name></person-group><article-title>HFA and ADHD: a direct comparison on state regulation and response inhibition</article-title><source>J Clin Exp Neuropsychol</source><year>2007</year><volume>29</volume><issue>4</issue><fpage>418</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1080/13803390600737990</pub-id><pub-id pub-id-type="pmid">17497565</pub-id></element-citation></ref><ref id="CR54"><mixed-citation publication-type="other">Robbins TW, Crockett MJ, Christian PM, Barry LJ (2010) Role of central serotonin in impulsivity and compulsivity: comparative studies in experimental animals and humans. Handbook of Behavioral Neuroscience. Elsevier. Volume 21, pp 415&#x02013;427</mixed-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>S</given-names></name><name><surname>Goddard</surname><given-names>L</given-names></name><name><surname>Dritschel</surname><given-names>B</given-names></name><name><surname>Wisley</surname><given-names>M</given-names></name><name><surname>Howlin</surname><given-names>P</given-names></name></person-group><article-title>Executive functions in children with autism spectrum disorders</article-title><source>Brain Cogn</source><year>2009</year><volume>71</volume><issue>3</issue><fpage>362</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.bandc.2009.06.007</pub-id><pub-id pub-id-type="pmid">19628325</pub-id></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rommelse</surname><given-names>NNJ</given-names></name><name><surname>Franke</surname><given-names>B</given-names></name><name><surname>Geurts</surname><given-names>HM</given-names></name><name><surname>Hartman</surname><given-names>CA</given-names></name><name><surname>Buitelaar</surname><given-names>JK</given-names></name></person-group><article-title>Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder</article-title><source>Eur Child Adolesc Psychiatry</source><year>2010</year><volume>19</volume><issue>3</issue><fpage>281</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1007/s00787-010-0092-x</pub-id><pub-id pub-id-type="pmid">20148275</pub-id></element-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rommelse</surname><given-names>NNJ</given-names></name><name><surname>Geurts</surname><given-names>HM</given-names></name><name><surname>Franke</surname><given-names>B</given-names></name><name><surname>Buitelaar</surname><given-names>JK</given-names></name><name><surname>Hartman</surname><given-names>CA</given-names></name></person-group><article-title>A review on cognitive and brain endophenotypes that may be common in autism spectrum disorder and attention-deficit/hyperactivity disorder and facilitate the search for pleiotropic genes</article-title><source>Neurosci Biobehav Rev</source><year>2011</year><volume>35</volume><issue>6</issue><fpage>1363</fpage><lpage>1396</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2011.02.015</pub-id><pub-id pub-id-type="pmid">21382410</pub-id></element-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubia</surname><given-names>K</given-names></name></person-group><article-title>&#x0201c;Cool&#x0201d; inferior frontostriatal dysfunction in attention-deficit/hyperactivity disorder versus &#x0201c;hot&#x0201d; ventromedial orbitofrontal-limbic dysfunction in conduct disorder: a review</article-title><source>Biol Psychiatry</source><year>2011</year><volume>69</volume><issue>12</issue><fpage>69</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2010.09.023</pub-id></element-citation></ref><ref id="CR59"><mixed-citation publication-type="other">Rubia K, Alegria A, Brinson H (2014) Imaging the ADHD brain: disorder-specificity, medication effects and clinical translation. Expert Rev Neurother 14(5):519&#x02013;538</mixed-citation></ref><ref id="CR60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Halari</surname><given-names>R</given-names></name><name><surname>Mohammad</surname><given-names>A-M</given-names></name><name><surname>Taylor</surname><given-names>E</given-names></name><name><surname>Brammer</surname><given-names>M</given-names></name></person-group><article-title>Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder</article-title><source>Biol Psychiatry</source><year>2011</year><volume>70</volume><issue>3</issue><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2011.04.018</pub-id><pub-id pub-id-type="pmid">21664605</pub-id></element-citation></ref><ref id="CR61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>F</given-names></name><name><surname>Cleare</surname><given-names>AJ</given-names></name><name><surname>Tunstall</surname><given-names>N</given-names></name><name><surname>Fu</surname><given-names>CHY</given-names></name><name><surname>Brammer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tryptophan depletion reduces right inferior prefrontal activation during response inhibition in fast, event-related fMRI</article-title><source>Psychopharmacology (Berl)</source><year>2005</year><volume>179</volume><issue>4</issue><fpage>791</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1007/s00213-004-2116-z</pub-id><pub-id pub-id-type="pmid">15887056</pub-id></element-citation></ref><ref id="CR62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Overmeyer</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>E</given-names></name><name><surname>Brammer</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>SCR</given-names></name><name><surname>Simmons</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI</article-title><source>Am J Psychiatry</source><year>1999</year><volume>156</volume><issue>6</issue><fpage>891</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1176/ajp.156.6.891</pub-id><pub-id pub-id-type="pmid">10360128</pub-id></element-citation></ref><ref id="CR63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Russell</surname><given-names>T</given-names></name><name><surname>Overmeyer</surname><given-names>S</given-names></name><name><surname>Brammer</surname><given-names>MJ</given-names></name><name><surname>Bullmore</surname><given-names>ET</given-names></name><name><surname>Sharma</surname><given-names>T</given-names></name><etal/></person-group><article-title>Mapping motor inhibition: conjunctive brain activations across different versions of go/no-go and stop tasks</article-title><source>Neuroimage</source><year>2001</year><volume>13</volume><issue>2</issue><fpage>250</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1006/nimg.2000.0685</pub-id><pub-id pub-id-type="pmid">11162266</pub-id></element-citation></ref><ref id="CR64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>AB</given-names></name><name><surname>Brammer</surname><given-names>MJ</given-names></name><name><surname>Taylor</surname><given-names>E</given-names></name></person-group><article-title>Right inferior prefrontal cortex mediates response inhibition while mesial prefrontal cortex is responsible for error detection</article-title><source>Neuroimage</source><year>2003</year><volume>20</volume><issue>1</issue><fpage>351</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/S1053-8119(03)00275-1</pub-id><pub-id pub-id-type="pmid">14527595</pub-id></element-citation></ref><ref id="CR65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>AB</given-names></name><name><surname>Brammer</surname><given-names>MJ</given-names></name><name><surname>Toone</surname><given-names>B</given-names></name><name><surname>Taylor</surname><given-names>E</given-names></name></person-group><article-title>Abnormal brain activation during inhibition and error detection in medication-naive adolescents with ADHD</article-title><source>Am J Psychiatry</source><year>2005</year><volume>162</volume><issue>6</issue><fpage>1067</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.162.6.1067</pub-id><pub-id pub-id-type="pmid">15930054</pub-id></element-citation></ref><ref id="CR66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>AB</given-names></name><name><surname>Taylor</surname><given-names>E</given-names></name><name><surname>Brammer</surname><given-names>M</given-names></name></person-group><article-title>Linear age-correlated functional development of right inferior fronto-striato-cerebellar networks during response inhibition and anterior cingulate during error-related processes</article-title><source>Hum Brain Mapp</source><year>2007</year><volume>28</volume><fpage>1163</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1002/hbm.20347</pub-id><pub-id pub-id-type="pmid">17538951</pub-id></element-citation></ref><ref id="CR67"><mixed-citation publication-type="other">Rutter M, Bailey A, Lord C (2003) The social communication questionnaire: manual western psychological services: Los Angeles</mixed-citation></ref><ref id="CR68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>N</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Daly</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>DGM</given-names></name></person-group><article-title>Neural correlates of executive function in autistic spectrum disorders</article-title><source>Biol Psychiatry</source><year>2006</year><volume>59</volume><issue>1</issue><fpage>7</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2005.06.007</pub-id><pub-id pub-id-type="pmid">16140278</pub-id></element-citation></ref><ref id="CR69"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sibley</surname><given-names>D</given-names></name><name><surname>Hanin</surname><given-names>I</given-names></name><name><surname>Kuhar</surname><given-names>M</given-names></name><name><surname>Skolnick</surname><given-names>P</given-names></name></person-group><source>Handbook of Contemporary Neuropharmacology Vol. 1</source><year>2007</year><publisher-loc>New York</publisher-loc><publisher-name>Wiley Blackwell</publisher-name></element-citation></ref><ref id="CR70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonoff</surname><given-names>E</given-names></name><name><surname>Pickles</surname><given-names>A</given-names></name><name><surname>Charman</surname><given-names>T</given-names></name><name><surname>Chandler</surname><given-names>S</given-names></name><name><surname>Loucas</surname><given-names>T</given-names></name><name><surname>Baird</surname><given-names>G</given-names></name></person-group><article-title>Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2008</year><volume>47</volume><issue>8</issue><fpage>921</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1097/CHI.0b013e318179964f</pub-id><pub-id pub-id-type="pmid">18645422</pub-id></element-citation></ref><ref id="CR71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinzig</surname><given-names>J</given-names></name><name><surname>Lehmkuhl</surname><given-names>G</given-names></name></person-group><article-title>What do we know about the serotonergic genetic heterogeneity in attention-deficit/hyperactivity and autistic disorders?</article-title><source>Psychopathology</source><year>2007</year><volume>40</volume><issue>5</issue><fpage>329</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1159/000105531</pub-id><pub-id pub-id-type="pmid">17630501</pub-id></element-citation></ref><ref id="CR72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spivak</surname><given-names>B</given-names></name><name><surname>Vered</surname><given-names>Y</given-names></name><name><surname>Yoran-Hegesh</surname><given-names>R</given-names></name><name><surname>Averbuch</surname><given-names>E</given-names></name><name><surname>Mester</surname><given-names>R</given-names></name><name><surname>Graf</surname><given-names>E</given-names></name><etal/></person-group><article-title>Circulatory levels of catecholamines, serotonin and lipids in attention deficit hyperactivity disorder</article-title><source>Acta Psychiatr Scand</source><year>1999</year><volume>99</volume><issue>4</issue><fpage>300</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.1999.tb07229.x</pub-id><pub-id pub-id-type="pmid">10223434</pub-id></element-citation></ref><ref id="CR73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tannock</surname><given-names>R</given-names></name><name><surname>Schachar</surname><given-names>R</given-names></name><name><surname>Carr</surname><given-names>R</given-names></name><name><surname>Chajczyk</surname><given-names>D</given-names></name><name><surname>Logan</surname><given-names>G</given-names></name></person-group><article-title>Effects of methylphenidate on inhibitory control in hyperactive children</article-title><source>J Abnorm Child Psychol</source><year>1989</year><volume>17</volume><issue>5</issue><fpage>473</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1007/BF00916508</pub-id><pub-id pub-id-type="pmid">2681316</pub-id></element-citation></ref><ref id="CR74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thirion</surname><given-names>B</given-names></name><name><surname>Pinel</surname><given-names>P</given-names></name><name><surname>Meriaux</surname><given-names>S</given-names></name><name><surname>Roche</surname><given-names>A</given-names></name><name><surname>Dehaene</surname><given-names>S</given-names></name><name><surname>Poline</surname><given-names>JB</given-names></name></person-group><article-title>Analysis of a large fMRI cohort: statistical and methodological issues for group analyses</article-title><source>Neuroimage</source><year>2007</year><volume>35</volume><issue>1</issue><fpage>105</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.11.054</pub-id><pub-id pub-id-type="pmid">17239619</pub-id></element-citation></ref><ref id="CR75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Meer</surname><given-names>JMJ</given-names></name><name><surname>Oerlemans</surname><given-names>AM</given-names></name><name><surname>van Steijn</surname><given-names>DJ</given-names></name><name><surname>Lappenschaar</surname><given-names>MGA</given-names></name><name><surname>de Sonneville</surname><given-names>LMJ</given-names></name><name><surname>Buitelaar</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Are autism spectrum disorder and attention-deficit/hyperactivity disorder different manifestations of one overarching disorder? Cognitive and symptom evidence from a clinical and population-based sample</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2012</year><volume>51</volume><issue>11</issue><fpage>1160</fpage><lpage>1172</lpage><pub-id pub-id-type="doi">10.1016/j.jaac.2012.08.024</pub-id><pub-id pub-id-type="pmid">23101742</pub-id></element-citation></ref><ref id="CR76"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>D</given-names></name></person-group><source>Wechsler Abbreviated Scale of Intelligence</source><year>1999</year><publisher-loc>San Antonio</publisher-loc><publisher-name>The Psychological Corporation</publisher-name></element-citation></ref><ref id="CR77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>DT</given-names></name><name><surname>Bymaster</surname><given-names>FP</given-names></name><name><surname>Engleman</surname><given-names>EA</given-names></name></person-group><article-title>Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: 20&#x000a0;years since its first publication</article-title><source>Life Sci</source><year>1995</year><volume>57</volume><issue>5</issue><fpage>411</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1016/0024-3205(95)00209-O</pub-id><pub-id pub-id-type="pmid">7623609</pub-id></element-citation></ref><ref id="CR78"><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organisation</collab></person-group><source>ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines</source><year>1994</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organisation</publisher-name></element-citation></ref><ref id="CR79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zafeiriou</surname><given-names>DI</given-names></name><name><surname>Ververi</surname><given-names>A</given-names></name><name><surname>Vargiami</surname><given-names>E</given-names></name></person-group><article-title>The serotonergic system: its role in pathogenesis and early developmental treatment of autism</article-title><source>Curr Neuropharmacol</source><year>2009</year><volume>7</volume><issue>2</issue><fpage>150</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.2174/157015909788848848</pub-id><pub-id pub-id-type="pmid">19949574</pub-id></element-citation></ref></ref-list></back></article>